Reports
Sale
Global Plasma Protein Therapeutics Market Size, Share, Growth: By Product Type: Immunoglobulin, Albumin, Plasma Derived Factor, Others; By Applications: Hemophilia, Idiopathic Thrombocytopenic Purpura, Primary Immunodeficiencies, Other Applications; By End User; Regional Analysis; Competitive Landscape; 2024-2032
Global Plasma Protein Therapeutics Market Outlook
The global plasma protein therapeutics market size was valued at USD 30.4 billion in 2023, driven by increasing demand for plasma protein therapies across the globe. The market size is anticipated to grow at a CAGR of 6.1% during the forecast period of 2024-2032 to achieve a value of USD 51.8 billion by 2032.
Plasma Protein Therapeutics: Introduction
Plasma-derived therapies play a crucial role in enhancing the quality of life for individuals by replacing missing or deficient proteins. These therapies are often a lifeline for patients who rely on them, necessitating regular infusions or injections throughout their lifetimes. The conditions treated by plasma protein therapies are typically categorized as rare diseases since they affect a relatively small percentage of the population, with many being genetic and chronic in nature.
Global Plasma Protein Therapeutics Market Analysis
The market is experiencing robust growth driven by the increase in demand for plasma protein therapies, particularly for conditions like hemophilia and Primary Immunodeficiency Disorders (PID), along with various other medical conditions. Novel drug therapies have gained high acceptance and accessibility, further fuelling the market expansion. Moreover, there is a significant increase in research and development efforts as well, particularly in the field of hemophilia therapy, contributing to the global plasma protein therapeutics market growth.
Additionally, the rising prevalence of autoimmune disorders has further amplified the demand for plasma protein therapeutics. Immunoglobulins are taking the lead in the product landscape, underscoring their importance in treating various medical conditions.
Global Plasma Protein Therapeutics Market Segmentations
Market Breakup by Product Type
- Immunoglobulin
- Albumin
- Plasma Derived Factor
- Others
Market Breakup by Applications
- Hemophilia
- Idiopathic Thrombocytopenic Purpura
- Primary Immunodeficiencies
- Other Applications
Market Breakup by End User
- Hospitals
- Home Care
- ASCs
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Plasma Protein Therapeutics Market Overview
The market is experiencing substantial growth driven by factors such as continuous product innovations in the field of plasma protein therapeutics adding options to existing treatment options and improving patient outcomes. The market is also driven by the increasing prevalence of autoimmune disorders and genetic disorders worldwide resulting in increased demand for these therapies, further propelling the plasma protein therapeutics market demand. The rising geriatric population that often requires such treatments has contributed to the market growth as well.
Government initiatives aimed at improving healthcare accessibility and affordability also play a pivotal role in fuelling the market's upward trajectory. Moreover, there is an escalating demand for albumin and an increased use of plasma proteins in pharmaceuticals, underlining their critical role in various medical treatments. Furthermore, the rising usage of immunoglobulin therapies has added to the market's overall growth, making the market a vibrant and evolving sector within the healthcare sector.
Global Plasma Protein Therapeutics Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- CSL Limited
- Baxter International
- Bio Products Laboratory Ltd
- Octapharma AG
- Kedrion, SpA
- Becton, Dickinson and Company
- Takeda Pharmaceutical
- Grifols, S.A.
- ADMA Biologics Inc
- Bayer AG
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product Type |
|
| Breakup by Applications |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Plasma Protein Therapeutics Market Overview
3.1 Global Plasma Protein Therapeutics Market Historical Value (2017-2023)
3.2 Global Plasma Protein Therapeutics Market Forecast Value (2024-2032)
4 Global Plasma Protein Therapeutics Market Landscape
4.1 Global Plasma Protein Therapeutics: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Plasma Protein Therapeutics: Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Applications
5 Global Plasma Protein Therapeutics Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Plasma Protein Therapeutics Market Segmentation
6.1 Global Plasma Protein Therapeutics Market by Product Type
6.1.1 Market Overview
6.1.2 Immunoglobulin
6.1.3 Albumin
6.1.4 Plasma Derived Factor
6.1.5 Others
6.2 Global Plasma Protein Therapeutics Market by Applications
6.2.1 Market Overview
6.2.2 Hemophilia
6.2.3 Idiopathic Thrombocytopenic Purpura
6.2.4 Primary Immunodeficiencies
6.2.5 Other Applications
6.3 Global Plasma Protein Therapeutics Market by End User
6.3.1 Market Overview
6.3.2 Hospitals
6.3.3 Home Care
6.3.4 ASCs
6.4 Global Plasma Protein Therapeutics Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Plasma Protein Therapeutics Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Global Protein Therapeutics Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Plasma Protein Therapeutics Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Plasma Protein Therapeutics Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Plasma Protein Therapeutics Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 CSL Limited
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Baxter International
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Bio Products Laboratory Ltd
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Octapharma AG
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Kedrion, SpA
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Becton, Dickinson and Company
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Takeda Pharmaceutical
17.7.1 Product Portfolio
17.7.2 Demographic Reach and Achievements
17.7.3 Mergers and Acquisitions
17.7.4 Certifications
17.8 Grifols, S.A.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 ADMA Biologics Inc
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Bayer AG
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
18 Key Opinion Leaders (KOL) Insights (Additional Insight)
19 Company Competitiveness Analysis (Additional Insight)
19.1 Very Small Companies
19.2 Small Companies
19.3 Mid-Sized Companies
19.4 Large Companies
19.5 Very Large Companies
20 Payment Methods (Additional Insight)
20.1 Government Funded
20.2 Private Insurance
20.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 30.4 billion in 2023, driven by the continuous product innovations in the field of plasma protein therapeutics.
The market is anticipated to grow at a CAGR of 6.1% during the forecast period of 2024-2032 to reach a market value of USD 51.8 billion by 2032.
The increasing prevalence of autoimmune disorders and genetic disorders are among the major factors driving the market growth.
An increase in the number of research and development activities, particularly in the field of hemophilia therapy, is a major trend influencing the market growth.
The major regional markets include North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
Different products in the market include immunoglobulin, albumin, plasma-derived factor, among other products.
They find wide applications in hemophilia, idiopathic thrombocytopenic purpura, and primary immunodeficiencies, among other applications.
End users in the market are hospitals, home care, and ASCs.
Key players involved in the market are CSL Limited, Baxter International, Bio Products Laboratory Ltd, Octapharma AG, Kedrion, SpA, Becton, Dickinson and Company, Takeda Pharmaceutical, Grifols, S.A., ADMA Biologics Inc, and Bayer AG.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER